Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Collegium Pharmaceutical Inc (COLL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 2,333,500 | $75,138,700 | +28% | 1.97% |
| 2. | Renaissance Technologies Jim Simons | 1,531,498 | $49,314,236 | +8% | 0.08% |
| 3. | 26,950,000 | $29,698,900 | +165% | 0.84% | |
| 4. | 23,000,000 | $25,460,195 | 1.32% | ||
| 5. | GLG Partners Noam Gottesman | 377,425 | $12,153,085 | +45% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.18 | 10,000 | Officer | 110,227 | 2017-05-12 | Filing | |
| $10.59 | 2,375 | Director | 2,375 | 2016-08-12 | Filing | |
| $12.00 | 3,930 | Large Shareholder | 65,270 | 2015-05-12 | Filing | |
| $12.00 | 196,070 | Large Shareholder | 3,256,572 | 2015-05-12 | Filing | |
| $12.00 | 150,000 | Large Shareholder, Director | 1,887,332 | 2015-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.62 | 9,593 | Officer | 53,816 | 2024-09-13 | Filing | |
| $37.46 | 977 | Officer | 119,184 | 2024-09-06 | Filing | |
| $39.14 | 2,400 | Officer | 120,161 | 2024-09-05 | Filing | |
| $38.18 | 16,848 | Officer | 122,561 | 2024-09-05 | Filing | |
| $33.22 | 700 | Officer | 139,409 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,786,993 | $178,123,645 | 0% | |
| 2. | 2,630,478 | $80,966,113 | 1.32% | |
| 3. | 2,312,786 | $71,187,552 | 0% | |
| 4. | 2,174,718 | $66,937,820 | 0.18% | |
| 5. | 1,569,151 | $48,298,467 | 0.03% |
News See All
10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
The major index futures are slightly in the red this morning.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call Transcript May 9, 2024Collegium Pharmaceutical, Inc. misses on earnings expectations.
5 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the five best small cap pharma stocks to invest in.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Call Transcript
Collegium Pharmaceutical, Inc. misses on earnings expectations. Reported EPS is $0.82 EPS, expectations were $1.33.
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now.
Reasons to Invest in Collegium Pharmaceutical (COLL)
Third Avenue Management, an investment management company based in New York City, released its “Small-Cap Value Fund” fourth quarter 2023 investor letter.
12 Cheap NASDAQ Stocks To Buy
In this piece, we will take a look at the 12 cheap NASDAQ stocks to buy.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Collegium Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.